Cyclo Therapeutics Inc. (CYTH)
NASDAQ: CYTH
· Real-Time Price · USD
0.72
-0.00 (-0.08%)
At close: Mar 25, 2025, 3:59 PM
-0.08% (1D)
| Bid | 0.68 |
| Market Cap | 23.59M |
| Revenue (ttm) | 870.73K |
| Net Income (ttm) | -24.8M |
| EPS (ttm) | -0.9 |
| PE Ratio (ttm) | -0.8 |
| Forward PE | -5.54 |
| Analyst | Hold |
| Ask | 0.72 |
| Volume | 186,806 |
| Avg. Volume (20D) | 1,761,627 |
| Open | 0.72 |
| Previous Close | 0.72 |
| Day's Range | 0.72 - 0.72 |
| 52-Week Range | 0.55 - 1.62 |
| Beta | -0.57 |
About CYTH
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, n...
Full Company ProfileAnalyst Forecast
According to 3 analyst ratings, the average rating for CYTH stock is "Hold." The 12-month stock price forecast is $0.95, which is an increase of 31.83% from the latest price.
Stock Forecasts2 months ago
Cyclo Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
8 months ago
Cyclo Therapeutics shares are trading lower after the company announced it agreed to merge with Rafael Holdings.
